ArticleInternational journal of retina and vitreous2026
Comparative incidence of endophthalmitis after intravitreal dexamethasone implant versus anti-VEGF injections: a retrospective study.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndophthalmitis is a rare but vision-threatening complication of intravitreal injections. Intravitreal dexamethasone implants and anti–vascular endothelial growth factor (anti-VEGF) agents are widely used, yet comparative real-world endophthalmitis rates remain incompletely defined. This study aimed to compare the incidence of endophthalmitis following intravitreal dexamethasone implant injections with that following anti-VEGF injections administered in outpatient retina practices.
methodsThis retrospective cohort study included all intravitreal injections performed between January 2019 and January 2024 at participating practices. Endophthalmitis events consistent with post-injection exogenous endophthalmitis occurring within two weeks of intravitreal injection were identified through clinical records. Chi-square testing was used to compare incidence rates between dexamethasone implant and anti-VEGF injections. Patient characteristics, visual acuity outcomes, and treatment approaches were assessed for confirmed endophthalmitis cases.
resultsA total of 330,572 intravitreal injections were analyzed, including 318,618 anti-VEGF injections and 11,954 dexamethasone implant injections. Endophthalmitis occurred more frequently after dexamethasone implant injections (0.125%, 15/11,954; 1.25 per 1,000 injections) than after anti-VEGF injections (0.033%, 106/318,618; 0.33 per 1,000 injections). This difference was statistically significant (χ² = 23.45, p = 2.3 × 10⁻⁷). Among dexamethasone-associated cases, 46.7% recovered to baseline or better visual acuity by six months, while the remaining patients experienced persistent visual deficits. Management commonly included intravitreal antibiotics with or without adjunct corticosteroids.
conclusionsIntravitreal dexamethasone implant injections were associated with a significantly higher incidence of endophthalmitis compared with anti-VEGF injections in this large outpatient cohort. Although nearly half of affected patients regained baseline vision, many had lasting impairment. These findings highlight the need for careful risk–benefit assessment when selecting intravitreal dexamethasone implants and underscore the importance of further study into modifiable risk factors and prevention strategies. A key limitation to consider is that clinically diagnosed endophthalmitis may include sterile intraocular inflammatory reactions following dexamethasone implant injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.